In the era of PET imaging, many sites of disease that are not visible on conventional imaging will be found on PSMA (prostate specific membrane antigen) PET. For men with castration-resistant prostate cancer with no evidence of metastases on conventional imaging but detectable disease on Prostate Specific Membrane Antigen (PSMA)-PET/CT scan, DECREASE will compare the treatment outcomes of men taking Darolutamide with or without treating the small metastasis seen on the PSMA PET scan with radiation therapy. Lead by A/Profs Shankar Siva and Arun Azad, DECREASE aims to determine that the combination (Darolutamide + RT) is better than Darolutamide alone at controlling PSA levels and further spread of prostate cancer.
A/Prof Shankar Siva, Peter MacCallum Cancer Centre, VIC
A/Prof Arun Azad, Peter MacCallum Cancer Centre, VIC
Clinical Trial Registration
The journey to becoming the 200th participant for the
The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing
For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Keep up to date with TROG news, subscribe to our community newsletter.
ABN: 45 132 672 292